Effect of ABCG2 , OCT1 , and ABCB1 ( MDR1 ) Gene Expression on Treatment-Free Remission in a EURO-SKI Subtrial-Reference-Cited by-同舟云学术

Effect of ABCG2 , OCT1 , and ABCB1 ( MDR1 ) Gene Expression on Treatment-Free Remission in a EURO-SKI Subtrial

Published:2018-04 Issue:4 Volume:18 Page:266-271
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Rinaldetti Sébastien,Pfirrmann Markus,Manz Kirsi^ORCID,Guilhot Joelle,Dietz Christian,Panagiotidis Panayiotidis,Spiess Birgit,Seifarth Wolfgang,Fabarius Alice,Müller Martin,Pagoni Maria,Dimou Maria,Dengler Jolanta,Waller Cornelius F.,Brümmendorf Tim H.,Herbst Regina,Burchert Andreas,Janβen Carsten,Goebeler Maria Elisabeth,Jost Philipp J.,Hanzel Stefan,Schafhausen Philippe,Prange-Krex Gabriele,Illmer Thomas,Janzen Viktor,Klausmann Martine,Eckert Robert,Büschel Gerd,Kiani Alexander,Hofmann Wolf-Karsten,Mahon François-Xavier,Saussele Susanne

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference35 articles.

1. The concept of treatment-free remission in chronic myeloid leukemia;Sauβele;Leukemia,2016

2. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial;Mahon;Lancet Oncol,2010

3. Cessation of tyrosine kinase inhibitors treatment in chronic myeloid leukemia patients with deep molecular response: results of the Euro-Ski trial;Mahon;Blood,2016

4. Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study;Hochhaus;Leukemia,2017

5. No differences in molecular relapse-free survival after stopping imatinib treatment of chronic myeloid leukemia between patients with prior 4.5 log reduction (MR4.5) but detectable and patients with undetectable disease in the EURO-SKI Trial;Pfirrmann;Blood,2016

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Study to Explore the Role of IDH1 (R132) Mutation on Imatinib Toxicity and Effect of ABCG2/OCT1 Expression on N-Desmethyl Imatinib Plasma Level in Egyptian Chronic Myeloid Leukemia Patients;Drug Research;2023-01-11

2. Real‐world efficacy and safety outcomes of imatinib treatment in patients with chronic myeloid leukemia: An Australian experience;Pharmacology Research & Perspectives;2022-09-14

3. Novel Dicarboximide BK124.1 Breaks Multidrug Resistance and Shows Anticancer Efficacy in Chronic Myeloid Leukemia Preclinical Models and Patients’ CD34+/CD38− Leukemia Stem Cells;Cancers;2022-07-27

4. OCT-1 Expression in Patients with Chronic Myeloid Leukemia: A Comparative Analysis with Respect to Response to Imatinib Treatment;Indian Journal of Hematology and Blood Transfusion;2022-04-11

5. Discontinuation of Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia: a Review of the Biological Factors Associated with Treatment-Free Remission;Current Oncology Reports;2022-02-10